12:01 PM EST - Correvio Pharma Corp. : Announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application for Brinavess™ (vernakalant hydrochloride, IV), an antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adult patients. The FDA assigned a target action date of December 24, 2019 under the Prescription Drug User-Fee Act. In its acceptance letter, the FDA stated that it is currently planning to hold an advisory committee meeting to discuss this application. Correvio Pharma Corp.
shares T.CORV are trading up $0.13 at $2.60.
